These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 7986587)

  • 21. Comparison of the specificities of IgG, IgG-subclass, IgA and IgM reactivities in African and European HIV-infected individuals with an HIV-1 clade C proteome-based array.
    Gallerano D; Ndlovu P; Makupe I; Focke-Tejkl M; Fauland K; Wollmann E; Puchhammer-Stöckl E; Keller W; Sibanda E; Valenta R
    PLoS One; 2015; 10(2):e0117204. PubMed ID: 25658330
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and immunogenicity of a V3 loop synthetic peptide conjugated to purified protein derivative in HIV-seronegative volunteers.
    Rubinstein A; Goldstein H; Pettoello-Mantovani M; Mizrachi Y; Bloom BR; Furer E; Althaus B; Que JU; Hasler T; Cryz SJ
    AIDS; 1995 Mar; 9(3):243-51. PubMed ID: 7755912
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Loss of antibody reactivity directed against the V3 domain of certain human immunodeficiency virus type 1 variants during disease progression.
    Schreiber M; Wachsmuth C; Müller H; Hagen C; Schmitz H; van Lunzen J
    J Gen Virol; 1996 Oct; 77 ( Pt 10)():2403-14. PubMed ID: 8887471
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relative reactivity of HIV-1 polyclonal plasma antibodies directed to V3 and MPER regions suggests immunodominance of V3 over MPER and dependence of high anti-V3 antibody titers on virus persistence.
    Andrabi R; Choudhary AK; Bala M; Kalra R; Prakash SS; Pandey RM; Luthra K
    Arch Virol; 2011 Oct; 156(10):1787-94. PubMed ID: 21735212
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neutralization of primary and T-cell line adapted isolates of human immunodeficiency virus type 1: role of V3-specific antibodies.
    Beddows S; Louisirirotchanakul S; Cheingsong-Popov R; Easterbrook PJ; Simmonds P; Weber J
    J Gen Virol; 1998 Jan; 79 ( Pt 1)():77-82. PubMed ID: 9460926
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibodies to the HIV-1 V3 loop in serum from infected persons contribute a major proportion of immune effector functions including complement activation, antibody binding, and neutralization.
    Spear GT; Takefman DM; Sharpe S; Ghassemi M; Zolla-Pazner S
    Virology; 1994 Nov; 204(2):609-15. PubMed ID: 7941328
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of the distribution of IgG and IgA antibodies in serum and various mucosal fluids of HIV type 1-infected subjects.
    Raux M; Finkielsztejn L; Salmon-Céron D; Bouchez H; Excler JL; Dulioust E; Grouin JM; Sicard D; Blondeau C
    AIDS Res Hum Retroviruses; 1999 Oct; 15(15):1365-76. PubMed ID: 10515152
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The majority of neutralizing Abs in HIV-1-infected patients recognize linear V3 loop sequences. Studies using HIV-1MN multiple antigenic peptides.
    Vogel T; Kurth R; Norley S
    J Immunol; 1994 Aug; 153(4):1895-904. PubMed ID: 7519220
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Studies on V3-specific cross-reactive T-cell responses in chimpanzees chronically infected with HIV-1IIIB.
    Nehete PN; Murthy KK; Satterfield WC; Arlinghaus RB; Sastry KJ
    AIDS; 1995 Jun; 9(6):567-72. PubMed ID: 7662194
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rapid selection for an N-linked oligosaccharide by monoclonal antibodies directed against the V3 loop of human immunodeficiency virus type 1.
    Schønning K; Jansson B; Olofsson S; Hansen JE
    J Gen Virol; 1996 Apr; 77 ( Pt 4)():753-8. PubMed ID: 8627264
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Secretory anti-human immunodeficiency virus (HIV) antibodies in colostrum and breast milk are not a major determinant of the protection of early postnatal transmission of HIV.
    Becquart P; Hocini H; Lévy M; Sépou A; Kazatchkine MD; Bélec L
    J Infect Dis; 2000 Feb; 181(2):532-9. PubMed ID: 10669336
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High antigenic cross-reactivity of the V3 consensus sequences of HIV-1 gp120.
    Baillou A; Brand D; Denis F; M'Boup S; Chout R; Goudeau A; Barin F
    AIDS Res Hum Retroviruses; 1993 Dec; 9(12):1209-15. PubMed ID: 7511395
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Binding and neutralization activity of human IgG1 and IgG3 from serum of HIV-infected individuals.
    Cavacini LA; Kuhrt D; Duval M; Mayer K; Posner MR
    AIDS Res Hum Retroviruses; 2003 Sep; 19(9):785-92. PubMed ID: 14585209
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Salivary sIgA response in HIV-1 infection.
    Skott P; Lucht E; Julander I; Dillner J; Björling E
    J Acquir Immune Defic Syndr; 1999 Jun; 21(2):73-80. PubMed ID: 10360797
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Simultaneous introduction of distinct HIV-1 subtypes into different risk groups in Russia, Byelorussia and Lithuania.
    Lukashov VV; Cornelissen MT; Goudsmit J; Papuashvilli MN; Rytik PG; Khaitov RM; Karamov EV; de Wolf F
    AIDS; 1995 May; 9(5):435-9. PubMed ID: 7639968
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
    Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
    J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.
    Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R
    Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Different immune response of mice immunized with conjugates containing multiple copies of either consensus or mixotope versions of the V3 loop peptide from human immunodeficiency virus type 1.
    Cruz LJ; Iglesias E; Aguilar JC; Cabrales A; Reyes O; Andreu D
    Bioconjug Chem; 2004; 15(5):1110-7. PubMed ID: 15366967
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular characterization of the circulating anti-HIV-1 gp120-specific B cell repertoire using antibody phage display libraries generated from pre-selected HIV-1 gp120 binding PBLs.
    Koefoed K; Farnaes L; Wang M; Svejgaard A; Burton DR; Ditzel HJ
    J Immunol Methods; 2005 Feb; 297(1-2):187-201. PubMed ID: 15777942
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pattern of antibody response against the V3 loop in children with vertically acquired immunodeficiency virus type 1 (HIV-1) infection.
    De Rossi A; Zanotto C; Mammano F; Ometto L; Del Mistro A; Chieco-Bianchi L
    AIDS Res Hum Retroviruses; 1993 Mar; 9(3):221-8. PubMed ID: 7682425
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.